Free Shipping on All Orders $75 Or More!

Your Trusted Brand for Over 35 Years

Health Protocols

References

References

  1. NSF. National Sleep Foundation. Insomnia. https://www.sleepfoundation.org/sleep-disorders/insomnia. Copyright 2019. Accessed 5/13/2019.
  2. CDC. Centers for Disease Control and Prevention. 1 in 3 adults don’t get enough sleep. https://www.cdc.gov/media/releases/2016/p0215-enough-sleep.html. 2/16/2016. Accessed 5/13/2019.
  3. Hirshkowitz M, Whiton K, Albert SM, et al. National Sleep Foundation’s sleep time duration recommendations: methodology and results summary. Sleep health. 2015;1(1):40-43.
  4. University H. Sleep and mental health. Harvard Mental Health Letter. 2010.
  5. Insititue NHLaB. Sleep Deprivation and Deficiency. 2018.
  6. Terauchi M, Hiramitsu S, Akiyoshi M, et al. Associations between anxiety, depression and insomnia in peri- and post-menopausal women. Maturitas. 2012;72(1):61-65.
  7. Ohayon MM, Caulet M, Lemoine P. Comorbidity of mental and insomnia disorders in the general population. Comprehensive psychiatry. 1998;39(4):185-197.
  8. Kakizaki M, Inoue K, Kuriyama S, et al. Sleep duration and the risk of prostate cancer: the Ohsaki Cohort Study. British journal of cancer. 2008;99(1):176-178.
  9. Verkasalo PK, Lillberg K, Stevens RG, et al. Sleep duration and breast cancer: a prospective cohort study. Cancer Res. 2005;65(20):9595-9600.
  10. Phillips B, Mannino DM. Do insomnia complaints cause hypertension or cardiovascular disease? Journal of clinical sleep medicine: JCSM: official publication of the American Academy of Sleep Medicine. 2007;3(5):489-494.
  11. Mayo Clinic. Insomnia. https://www.mayoclinic.org/diseases-conditions/insomnia/symptoms-causes/syc-20355167. 10/15/2016. Accessed 5/13/2019.
  12. Kripke DF. I petitioned the FDA to restrict hypnotics: here is why. Sleep Med. 2016;23:119-120.
  13. Kripke DF. Hypnotic drug risks of mortality, infection, depression, and cancer: but lack of benefit. F1000Research. 2016;5:918.
  14. Kripke DF, Langer RD, Kline LE. Hypnotics' association with mortality or cancer: a matched cohort study. BMJ open. 2012;2(1):e000850.
  15. Yang CM, Lin SC, Hsu SC, Cheng CP. Maladaptive sleep hygiene practices in good sleepers and patients with insomnia. Journal of health psychology. 2010;15(1):147-155.
  16. Lande RG, Gragnani C. Nonpharmacologic approaches to the management of insomnia. J Am Osteopath Assoc. 2010;110(12):695-701.
  17. Xu Z, Jiang X, Li W, Gao D, Li X, Liu J. Propofol-induced sleep: efficacy and safety in patients with refractory chronic primary insomnia. Cell Biochem Biophys. 2011;60(3):161-166.
  18. Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline. Journal of clinical sleep medicine: JCSM: official publication of the American Academy of Sleep Medicine. 2017;13(2):307-349.
  19. Saddichha S. Diagnosis and treatment of chronic insomnia. Annals of Indian Academy of Neurology. 2010;13(2):94-102.
  20. Roth T, Roehrs T. Insomnia: epidemiology, characteristics, and consequences. Clinical cornerstone. 2003;5(3):5-15.
  21. NSF. National Sleep Foundation. Menopause and Sleep. https://www.sleepfoundation.org/articles/menopause-and-sleep. Copyright 2019. Accessed 4/2/2019.
  22. Silva BH, Martinez D, Wender MC. A randomized, controlled pilot trial of hormone therapy for menopausal insomnia. Archives of women's mental health. 2011;14(6):505-508.
  23. Barrett-Connor E, Dam TT, Stone K, Harrison SL, Redline S, Orwoll E. The association of testosterone levels with overall sleep quality, sleep architecture, and sleep-disordered breathing. J Clin Endocrinol Metab. 2008;93(7):2602-2609.
  24. Kim SD, Cho KS. Obstructive Sleep Apnea and Testosterone Deficiency. The world journal of men's health. 2019;37(1):12-18.
  25. Wittert G. The relationship between sleep disorders and testosterone in men. Asian journal of andrology. 2014;16(2):262-265.
  26. Burschtin O, Wang J. Testosterone Deficiency and Sleep Apnea. Sleep medicine clinics. 2016;11(4):525-529.
  27. Canguven O, Salepci B, Albayrak S, Selimoglu A, Balaban M, Bulbul M. Is there a correlation between testosterone levels and the severity of the disease in male patients with obstructive sleep apnea? Arch Ital Urol Androl. 2010;82(4):143-147.
  28. Mayo Clinic. Symptoms & causes. Obstructive sleep apnea. https://www.mayoclinic.org/diseases-conditions/obstructive-sleep-apnea/symptoms-causes/syc-20352090. 3/6/2018. Accessed 4/2/2019.
  29. NSF. National Sleep Foundation. Sleep Apnea. https://www.sleepfoundation.org/sleep-apnea. Copyright 2019. Accessed 4/2/2019.
  30. Punjabi NM. The epidemiology of adult obstructive sleep apnea. Proceedings of the American Thoracic Society. 2008;5(2):136-143.
  31. Drager LF, Polotsky VY, Lorenzi-Filho G. Obstructive sleep apnea: an emerging risk factor for atherosclerosis. Chest. 2011;140(2):534-542.
  32. AHA. American Heart Association. Sleep Apnea and Heart Disease, Stroke. https://www.heart.org/en/health-topics/consumer-healthcare/sleep-apnea-and-heart-disease-stroke. 7/31/2015. Accessed 5/13/2019.
  33. Gottlieb DJ, Yenokyan G, Newman AB, et al. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study. Circulation. 2010;122(4):352-360.
  34. Pedrosa RP, Drager LF, Gonzaga CC, et al. Obstructive sleep apnea: the most common secondary cause of hypertension associated with resistant hypertension. Hypertension. 2011;58(5):811-817.
  35. Aronsohn RS, Whitmore H, Van Cauter E, Tasali E. Impact of untreated obstructive sleep apnea on glucose control in type 2 diabetes. American journal of respiratory and critical care medicine. 2010;181(5):507-513.
  36. Nieto FJ, Peppard PE, Young T, Finn L, Hla KM, Farre R. Sleep-disordered breathing and cancer mortality: results from the Wisconsin Sleep Cohort Study. American journal of respiratory and critical care medicine. 2012;186(2):190-194.
  37. Yaggi HK, Concato J, Kernan WN, Lichtman JH, Brass LM, Mohsenin V. Obstructive sleep apnea as a risk factor for stroke and death. The New England journal of medicine. 2005;353(19):2034-2041.
  38. Morin CM, LeBlanc M, Daley M, Gregoire JP, Merette C. Epidemiology of insomnia: prevalence, self-help treatments, consultations, and determinants of help-seeking behaviors. Sleep Med. 2006;7(2):123-130.
  39. Buysse DJ, Germain A. Diagnosis, Epidemiology, and Consequences of Insomnia. Primary Psychiatry. 2005;12(8):37-44.
  40. Baroni A, Hernandez M, Grant MC, Faedda GL. Sleep Disturbances in Pediatric Bipolar Disorder: A Comparison between Bipolar I and Bipolar NOS. Frontiers in psychiatry. 2012;3:22.
  41. Yokoyama E, Ohida T, Tamaki T, et al. Association between Depression and Insomnia Subtypes: A Longitudinal Study on the Elderly in Japan. Sleep. 2010;33(12):1693-1702.
  42. NSF. National Sleep Foundation. Sleep Hygiene, Insomnia and Mental Health. https://www.sleepfoundation.org/articles/sleep-hygiene-insomnia-and-mental-health. Copyright 2019. Accessed 4/2/2019.
  43. Roane BM, Taylor DJ. Adolescent Insomnia as a Risk Factor for Early Adult Depression and Substance Abuse. Sleep. 2008;31(10):1351-1356.
  44. Singareddy R, Vgontzas AN, Fernandez-Mendoza J, et al. Risk factors for incident chronic insomnia: a general population prospective study. Sleep Med. 2012;13(4):346-353.
  45. Franzen PL, Buysse DJ, Dahl RE, Thompson W, Siegle GJ. Sleep deprivation alters pupillary reactivity to emotional stimuli in healthy young adults. Biological Psychology. 2009;80(3):300-305.
  46. Medicine. AAoS. Insomnia may cause dysfunction in emotional brain circuitry. Science Daily. 2013.
  47. Bastien CH, St-Jean G, Morin CM, Turcotte I, Carrier J. Chronic psychophysiological insomnia: hyperarousal and/or inhibition deficits? An ERPs investigation. Sleep. 2008;31(6):887-898.
  48. Espie CA. Insomnia: conceptual issues in the development, persistence, and treatment of sleep disorder in adults. Annual review of psychology. 2002;53:215-243.
  49. van de Laar M, Pevernagie D, van Mierlo P, Overeem S. Psychiatric Comorbidity and Aspects of Cognitive Coping Negatively Predict Outcome in Cognitive Behavioral Treatment of Psychophysiological Insomnia. Behavioral sleep medicine. 2015;13(2):140-156.
  50. National Heart, Lung, and Blood Institiute. Insomnia. https://www.nhlbi.nih.gov/health-topics/insomnia. 11/9/2011. Accessed 5/13/2019.
  51. NSF. National Sleep Foundation. What causes insomnia? https://www.sleepfoundation.org/insomnia/what-causes-insomnia. Copyright 2019. Accessed 4/2/2019.
  52. Dhaval Patel MJS, MD; Pragnesh Patel, MD. Insomnia in the Elderly: A Review. Journal of Clinical Sleep Medicine. 2018;14(6).
  53. Carroll JE, Irwin MR, Levine M, et al. Epigenetic Aging and Immune Senescence in Women With Insomnia Symptoms: Findings From the Women’s Health Initiative Study. Biological psychiatry. 2017;81(2):136-144.
  54. Foral PK, Jon; Dewan, Naresh; Malesker, Mark. Medication-Induced Sleep Disturbances. The Consultant Pharmacist. 2011:414-425(412).
  55. NSF. National Sleep Foundation. How Medications May Affect Sleep. https://www.sleepfoundation.org/articles/how-medications-may-affect-sleep. Copyright 2019. Accessed 4/2/2019.
  56. Neikrug AB, Ancoli-Israel S. Sleep disorders in the older adult - a mini-review. Gerontology. 2010;56(2):181-189.
  57. Moghadam-Kia S, Werth VP. Prevention and treatment of systemic glucocorticoid side effects. Int J Dermatol. 2010;49(3):239-248.
  58. Nerbass FB, Pedrosa RP, Genta PR, Drager LF, Lorenzi-Filho G. Calcium channel blockers are independently associated with short sleep duration in hypertensive patients with obstructive sleep apnea. J Hypertens. 2011;29(6):1236-1241.
  59. Bercovitch RS, Tsai SC. Respiratory medications and sleep. Current Respiratory Care Reports. 2012;1(2):123-130.
  60. Roehrs T, Roth T. Caffeine: sleep and daytime sleepiness. Sleep medicine reviews. 2008;12(2):153-162.
  61. Chaudhary NS, Grandner MA, Jackson NJ, Chakravorty S. Caffeine consumption, insomnia, and sleep duration: Results from a nationally representative sample. Nutrition (Burbank, Los Angeles County, Calif). 2016;32(11):1193-1199.
  62. Clark I, Landolt HP. Coffee, caffeine, and sleep: A systematic review of epidemiological studies and randomized controlled trials. Sleep medicine reviews. 2017;31:70-78.
  63. Youngberg MR, Karpov IO, Begley A, Pollock BG, Buysse DJ. Clinical and physiological correlates of caffeine and caffeine metabolites in primary insomnia. Journal of clinical sleep medicine: JCSM: official publication of the American Academy of Sleep Medicine. 2011;7(2):196-203.
  64. Jaehne A, Loessl B, Barkai Z, Riemann D, Hornyak M. Effects of nicotine on sleep during consumption, withdrawal and replacement therapy. Sleep medicine reviews. 2009;13(5):363-377.
  65. Brook JS, Zhang C, Rubenstone E, Brook DW. Insomnia in adults: the impact of earlier cigarette smoking from adolescence to adulthood. Journal of addiction medicine. 2015;9(1):40-45.
  66. Sabanayagam C, Shankar A. The association between active smoking, smokeless tobacco, second-hand smoke exposure and insufficient sleep. Sleep medicine. 2011;12(1):7-11.
  67. Hendler RA, Ramchandani VA, Gilman J, Hommer DW. Stimulant and sedative effects of alcohol. Curr Top Behav Neurosci. 2013;13:489-509.
  68. Brower KJ, Myra Kim H, Strobbe S, Karam-Hage MA, Consens F, Zucker RA. A randomized double-blind pilot trial of gabapentin versus placebo to treat alcohol dependence and comorbid insomnia. Alcohol Clin Exp Res. 2008;32(8):1429-1438.
  69. Stein MD, Friedmann PD. Disturbed Sleep and Its Relationship to Alcohol Use. Substance Abuse. 2006;26(1):1-13.
  70. Brooks AT, Wallen GR. Sleep Disturbances in Individuals with Alcohol-Related Disorders: A Review of Cognitive-Behavioral Therapy for Insomnia (CBT-I) and Associated Non-Pharmacological Therapies. Substance Abuse: Research and Treatment. 2014;8:SART.S18446.
  71. Zhabenko N, Wojnar M, Brower KJ. Prevalence and Correlates of Insomnia in a Polish Sample of Alcohol-Dependent Patients. 2012;36(9):1600-1607.
  72. Brower KJ, Krentzman A, Robinson EAR. Persistent insomnia, abstinence, and moderate drinking in alcohol-dependent individuals. The American journal on addictions. 2011;20(5):435-440.
  73. Baglioni C, Spiegelhalder K, Lombardo C, Riemann D. Sleep and emotions: A focus on insomnia. Sleep medicine reviews. 2010;14(4):227-238.
  74. Fernández-Mendoza J, Vela-Bueno A, Vgontzas AN, et al. Cognitive-Emotional Hyperarousal as a Premorbid Characteristic of Individuals Vulnerable to Insomnia. 2010;72(4):397-403.
  75. Kolla BP, Auger RR. Jet lag and shift work sleep disorders: how to help reset the internal clock. Cleveland Clinic journal of medicine. 2011;78(10):675-684.
  76. NSF. National Sleep Foundation. Shift Work Disorder. https://www.sleepfoundation.org/sleep-disorders/shift-work-disorder. Copyright 2019. Accessed 4/2/2019.
  77. Bertisch SM, Mittleman MA, Redline S, et al. Insomnia with objective short sleep duration and risk of incident cardiovascular disease and all-cause mortality: Sleep Heart Health Study. Sleep. 2018;41(6).
  78. Vatten LJ, Strand LB, Laugsand LE, Platou C, Janszky I. Insomnia and the risk of incident heart failure: a population study. European Heart Journal. 2013;35(21):1382-1393.
  79. Domínguez F, Fuster V, Fernández-Alvira JM, et al. Association of Sleep Duration and Quality With Subclinical Atherosclerosis. Journal of the American College of Cardiology. 2019;73(2):134-144.
  80. Ibarra-Coronado EG, Pantaleón-Martinez, Velazquéz-Moctezuma J, et al. The Bidirectional Relationship between Sleep and Immunity against Infections %J Journal of Immunology Research. 2015;2015:14.
  81. Aldabal L, Bahammam AS. Metabolic, endocrine, and immune consequences of sleep deprivation. The open respiratory medicine journal. 2011;5:31-43.
  82. Bonnet MH, Arand DL. Hyperarousal and insomnia: state of the science. Sleep medicine reviews. 2010;14(1):9-15.
  83. Zhang J, Ma RC, Kong AP, et al. Relationship of sleep quantity and quality with 24-hour urinary catecholamines and salivary awakening cortisol in healthy middle-aged adults. Sleep. 2011;34(2):225-233.
  84. Chiodini I, Scillitani A. [Role of cortisol hypersecretion in the pathogenesis of osteoporosis]. Recenti progressi in medicina. 2008;99(6):309-313.
  85. Butcher SK, Killampalli V, Lascelles D, Wang K, Alpar EK, Lord JM. Raised cortisol:DHEAS ratios in the elderly after injury: potential impact upon neutrophil function and immunity. Aging Cell. 2005;4(6):319-324.
  86. Duong M, Cohen JI, Convit A. High cortisol levels are associated with low quality food choice in type 2 diabetes. Endocrine. 2012;41(1):76-81.
  87. Haack M, Scott-Sutherland J, Santangelo G, Simpson NS, Sethna N, Mullington JM. Pain sensitivity and modulation in primary insomnia. 2012;16(4):522-533.
  88. Schuh-Hofer S, Wodarski R, Pfau DB, et al. One night of total sleep deprivation promotes a state of generalized hyperalgesia: A surrogate pain model to study the relationship of insomnia and pain. PAIN®. 2013;154(9):1613-1621.
  89. Harsora P, Kessmann J. Nonpharmacologic management of chronic insomnia. American family physician. 2009;79(2):125-130.
  90. CDC. Centers for Disease Control and Prevention. Sleep and Sleep Disorders: Tips for Better Sleep. https://www.cdc.gov/sleep/about_sleep/sleep_hygiene.html. Last updated 7/15/2016. Accessed 4/2/2019. 2016.
  91. Gellis LA, Park A, Stotsky MT, Taylor DJ. Associations between sleep hygiene and insomnia severity in college students: cross-sectional and prospective analyses. Behav Ther. 2014;45(6):806-816.
  92. Holt B, Tran S, Cochran A, Saffle J, Lin H, Faraklas I. Impact of a Nursing-Driven Sleep Hygiene Protocol on Sleep Quality. Journal of Burn Care & Research. 2013;34(2):249-254.
  93. McCurry SM, Logsdon RG, Teri L, Vitiello MV. Sleep disturbances in caregivers of persons with dementia: contributing factors and treatment implications. Sleep medicine reviews. 2007;11(2):143-153.
  94. Hoch CC, Reynolds CF, 3rd, Buysse DJ, et al. Protecting sleep quality in later life: a pilot study of bed restriction and sleep hygiene. The journals of gerontology Series B, Psychological sciences and social sciences. 2001;56(1):P52-59.
  95. Miller CB, Espie CA, Epstein DR, et al. The evidence base of sleep restriction therapy for treating insomnia disorder. Sleep medicine reviews. 2014;18(5):415-424.
  96. Mayo Clinic. Insomnia treatment: Cognitive behavioral therapy instead of sleeping pills. https://www.mayoclinic.org/diseases-conditions/insomnia/in-depth/insomnia-treatment/art-20046677. 9/28/2016. Accessed 4/2/2019.
  97. Edinger JD, Wohlgemuth WK, Radtke RA, Marsh GR, Quillian RE. Cognitive behavioral therapy for treatment of chronic primary insomnia: a randomized controlled trial. JAMA. 2001;285(14):1856-1864.
  98. Smith MT, Neubauer DN. Cognitive behavior therapy for chronic insomnia. Clinical cornerstone. 2003;5(3):28-40.
  99. Smith MT, Huang MI, Manber R. Cognitive behavior therapy for chronic insomnia occurring within the context of medical and psychiatric disorders. Clin Psychol Rev. 2005;25(5):559-592.
  100. Savard J, Simard S, Ivers H, Morin CM. Randomized study on the efficacy of cognitive-behavioral therapy for insomnia secondary to breast cancer, part I: Sleep and psychological effects. J Clin Oncol. 2005;23(25):6083-6096.
  101. Lancee J, Eisma MC, van Straten A, Kamphuis JH. Sleep-Related Safety Behaviors and Dysfunctional Beliefs Mediate the Efficacy of Online CBT for Insomnia: A Randomized Controlled Trial. Cognitive behaviour therapy. 2015;44(5):406-422.
  102. Mitchell MD, Gehrman P, Perlis M, Umscheid CA. Comparative effectiveness of cognitive behavioral therapy for insomnia: a systematic review. BMC Family Practice. 2012;13(1):40.
  103. Kripke DF. Hypnotic drug risks of mortality, infection, depression, and cancer: but lack of benefit. F1000Research. 2018;5:918-918.
  104. Brasure M, MacDonald R, Fuchs E, et al. AHRQ Comparative Effectiveness Reviews. In: Management of Insomnia Disorder. Rockville (MD): Agency for Healthcare Research and Quality (US); 2015.
  105. Ong JC, Ulmer CS, Manber R. Improving sleep with mindfulness and acceptance: A metacognitive model of insomnia. Behaviour Research and Therapy. 2012;50(11):651-660.
  106. Gross CR, Kreitzer MJ, Reilly-Spong M, et al. Mindfulness-Based Stress Reduction Versus Pharmacotherapy for Chronic Primary Insomnia: A Randomized Controlled Clinical Trial. EXPLORE. 2011;7(2):76-87.
  107. Afonso RF, Hachul H, Kozasa EH, et al. Yoga decreases insomnia in postmenopausal women: a randomized clinical trial. 2012;19(2):186-193.
  108. Dhaval Patel MJS, MD; Pragnesh Patel, MD. Insomnia in the Elderly: A Review. Journal of clinical sleep medicine: JCSM: official publication of the American Academy of Sleep Medicine. 2018;14(6):1017-1024.
  109. Mayo Clinic. Sleep aids: Understand over-the-counter options. https://www.mayoclinic.org/healthy-lifestyle/adult-health/in-depth/sleep-aids/art-20047860. 2/17/2018. Accessed 4/2/2019.
  110. Randall S, Roehrs TA, Roth T. Over-the-counter sleep aid medications and insomnia. Primary Psychiatry. 2008;15(5):52.
  111. Mayo Clinic. Sleep aids: Understand over-the-counter options. https://www.mayoclinic.org/healthy-lifestyle/adult-health/in-depth/sleep-aids/art-20047860. 2/17/2018. Accessed 5/13/2019.
  112. Stone JA, Lester CA, Aboneh EA, Phelan CH, Welch LL, Chui MA. A preliminary examination of over-the-counter medication misuse rates in older adults. Research in Social and Administrative Pharmacy. 2017;13(1):187-192.
  113. Abraham O, Schleiden L, Albert SMJIJoCP. Over-the-counter medications containing diphenhydramine and doxylamine used by older adults to improve sleep. 2017;39(4):808-817.
  114. Lieberman JA. Update on the safety considerations in the management of insomnia with hypnotics: incorporating modified-release formulations into primary care. Primary care companion to the Journal of clinical psychiatry. 2007;9(1):25-31.
  115. Bourgeois J, Elseviers, M.M., Van Bortel, L. et al. . One-Year Evolution of Sleep Quality in Older Users of Benzodiazepines: A Longitudinal Cohort Study in Belgian Nursing Home Residents. Drugs and Aging. 2014;31(677).
  116. Medicine NUSNLo. Zaleplon. 2018.
  117. Greenblatt DJ, Roth T. Zolpidem for insomnia. Expert opinion on pharmacotherapy. 2012;13(6):879-893.
  118. Roth T, Walsh JK, Krystal A, Wessel T, Roehrs TA. An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia. Sleep Med. 2005;6(6):487-495.
  119. Ancoli-Israel S, Krystal AD, McCall WV, et al. A 12-week, randomized, double-blind, placebo-controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep. 2010;33(2):225-234.
  120. FDA. U.S. Food & Drug Administration. FDA Drug Safety Communication: FDA warns of next-day impairment with sleep aid Lunesta (eszopiclone) and lowers recommended dose. https://www.fda.gov/drugs/drugsafety/ucm397260.htm. 5/15/2014. Accessed 4/2/2019.
  121. Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN. Adverse Effects of Hypnotic Medications. Journal of clinical sleep medicine: JCSM: official publication of the American Academy of Sleep Medicine. 2017;13(6):839-839.
  122. FDA. FDA requires stronger warnings about rare but serious incidents related to certain prescription insomnia medicines. https://www.fda.gov/news-events/press-announcements/fda-requires-stronger-warnings-about-rare-serious-incidents-related-certain-prescription-insomnia. Published 2019. Updated Apr. 30, 2019. Accessed May 8, 2019.
  123. University H. Overcoming insomnia. Harvard Mental Health Letter. 2011.
  124. Roth T, Rogowski R, Hull S, et al. Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in adults with primary insomnia. Sleep. 2007;30(11):1555-1561.
  125. Krystal AD, Durrence HH, Scharf M, et al. Efficacy and Safety of Doxepin 1 mg and 3 mg in a 12-week Sleep Laboratory and Outpatient Trial of Elderly Subjects with Chronic Primary Insomnia. Sleep. 2010;33(11):1553-1561.
  126. Krystal AD, Lankford A, Durrence HH, et al. Efficacy and safety of doxepin 3 and 6 mg in a 35-day sleep laboratory trial in adults with chronic primary insomnia. Sleep. 2011;34(10):1433-1442.
  127. Walsh JK, Erman M, Erwin C, et al. Subjective hypnotic efficacy of trazodone and zolpidem in DSMIII–R primary insomnia. Human Psychopharmacology: Clinical and Experimental. 1998;13(3):191-198.
  128. Park PKNaSH. Antidepressant management of insomnia disorder in the absence of a mood disorder. Mental Health Clinician. 2014;4:41-46.
  129. Roth AJ, McCall WV, Liguori A. Cognitive, psychomotor and polysomnographic effects of trazodone in primary insomniacs. 2011;20(4):552-558.
  130. Camargos EF, Louzada LL, Quintas JL, Naves JOS, Louzada FM, Nóbrega OT. Trazodone Improves Sleep Parameters in Alzheimer Disease Patients: A Randomized, Double-Blind, and Placebo-Controlled Study. The American Journal of Geriatric Psychiatry. 2014;22(12):1565-1574.
  131. NIH. National Institutes of Health. https://medlineplus.gov/druginfo/meds/a682388.html. Amitriptyline. Last updated 5/7/2019. Accessed 5/13/2019.
  132. Karsten J, Hagenauw LA, Kamphuis J, Lancel M. Low doses of mirtazapine or quetiapine for transient insomnia: A randomised, double-blind, cross-over, placebo-controlled trial. Journal of Psychopharmacology. 2017;31(3):327-337.
  133. Wichniak A, Wierzbicka A, Walęcka M, Jernajczyk WJCPR. Effects of Antidepressants on Sleep. 2017;19(9):63.
  134. Kripke DF, Garfinkel L, Wingard DL, Klauber MR, Marler MR. Mortality associated with sleep duration and insomnia. Archives of general psychiatry. 2002;59(2):131-136.
  135. Liu J, Clough SJ, Hutchinson AJ, Adamah-Biassi EB, Popovska-Gorevski M, Dubocovich ML. MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective. Annual review of pharmacology and toxicology. 2016;56:361-383.
  136. Miyamoto M. [A novel therapeutic drug: ramelteon]. Nihon rinsho Japanese journal of clinical medicine. 2009;67(8):1595-1600.
  137. CH B Praveena Devi SS, N Kusuma Kumari and JVC, Sharma AK. A review on insomnia: The sleep disorder. The Pharma Innovation. 2018;7(12):227-230.
  138. Turek FW, Gillette MU. Melatonin, sleep, and circadian rhythms: rationale for development of specific melatonin agonists. Sleep Med. 2004;5(6):523-532.
  139. Kato K, Hirai K, Nishiyama K, et al. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology. 2005;48(2):301-310.
  140. Sateia MJ, Kirby-Long P, Taylor JL. Efficacy and clinical safety of ramelteon: an evidence-based review. Sleep medicine reviews. 2008;12(4):319-332.
  141. Roth T, Seiden D, Sainati S, Wang-Weigand S, Zhang J, Zee P. Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Sleep Med. 2006;7(4):312-318.
  142. Zammit G, Erman M, Wang-Weigand S, Sainati S, Zhang J, Roth T. Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine. 2007;3(5):495-504.
  143. Rajaratnam SM, Polymeropoulos MH, Fisher DM, et al. Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials. Lancet. 2009;373(9662):482-491.
  144. Ochoa-Sanchez R, Comai S, Lacoste B, et al. Promotion of non-rapid eye movement sleep and activation of reticular thalamic neurons by a novel MT2 melatonin receptor ligand. J Neurosci. 2011;31(50):18439-18452.
  145. Spadoni G, Bedini A, Rivara S, Mor M. Melatonin receptor agonists: new options for insomnia and depression treatment. CNS neuroscience & therapeutics. 2011;17(6):733-741.
  146. Posa L, De Gregorio D, Gobbi G, Comai S. Targeting Melatonin MT2 Receptors: A Novel Pharmacological Avenue for Inflammatory and Neuropathic Pain. Current medicinal chemistry. 2018;25(32):3866-3882.
  147. Kripke DF. Is suvorexant a better choice than alternative hypnotics? F1000Research. 2015;4:456-456.
  148. Herring WJ, Connor KM, Ivgy-May N, et al. Suvorexant in Patients With Insomnia: Results From Two 3-Month Randomized Controlled Clinical Trials. Biological psychiatry. 2016;79(2):136-148.
  149. Michelson D, Snyder E, Paradis E, et al. Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014;13(5):461-471.
  150. Sangare A, Dubourget R, Geoffroy H, Gallopin T, Rancillac A. Serotonin differentially modulates excitatory and inhibitory synaptic inputs to putative sleep-promoting neurons of the ventrolateral preoptic nucleus. Neuropharmacology. 2016;109:29-40.
  151. Nonogaki K. Serotonin conflict in sleep-feeding. Vitamins and hormones. 2012;89:223-239.
  152. Landolt HP, Wehrle R. Antagonism of serotonergic 5-HT2A/2C receptors: mutual improvement of sleep, cognition and mood? Eur J Neurosci. 2009;29(9):1795-1809.
  153. Nakamaru-Ogiso E, Miyamoto H, Hamada K, Tsukada K, Takai K. Novel biochemical manipulation of brain serotonin reveals a role of serotonin in the circadian rhythm of sleep-wake cycles. Eur J Neurosci. 2012;35(11):1762-1770.
  154. Xiong Y, Ullman B, Choi JS, et al. Synthesis and in vivo evaluation of phenethylpiperazine amides: selective 5-hydroxytryptamine(2A) receptor antagonists for the treatment of insomnia. J Med Chem. 2010;53(15):5696-5706.
  155. Al-Shamma HA, Anderson C, Chuang E, et al. Nelotanserin, a novel selective human 5-hydroxytryptamine2A inverse agonist for the treatment of insomnia. The Journal of pharmacology and experimental therapeutics. 2010;332(1):281-290.
  156. Song J, Um YH, Kim TW, Kim SM, Kwon SY, Hong S-C. Sleep and Anesthesia. Sleep Med Res. 2018;9(1):11-19.
  157. Dispersyn G, Ph.D., Pain L, M.D., Touitou Y, Ph.D. Propofol Anesthesia Significantly Alters Plasma Blood Levels of Melatonin in Rats. Anesthesiology: The Journal of the American Society of Anesthesiologists. 2010;112(2):333-337.
  158. Foundation NS. Melatonin and Sleeo. 2019.
  159. Cardinali DP, Srinivasan V, Brzezinski A, Brown GM. Melatonin and its analogs in insomnia and depression. Journal of pineal research. 2012;52(4):365-375.
  160. Ferracioli-Oda E, Qawasmi A, Bloch MH. Meta-Analysis: Melatonin for the Treatment of Primary Sleep Disorders. PLOS ONE. 2013;8(5):e63773.
  161. van Geijlswijk IM, van der Heijden KB, Egberts AC, Korzilius HP, Smits MG. Dose finding of melatonin for chronic idiopathic childhood sleep onset insomnia: an RCT. Psychopharmacology. 2010;212(3):379-391.
  162. Lemoine P, Wade AG, Katz A, Nir T, Zisapel N. Efficacy and safety of prolonged-release melatonin for insomnia in middle-aged and elderly patients with hypertension: a combined analysis of controlled clinical trials. Integrated blood pressure control. 2012;5:9-17.
  163. Garfinkel D, Zorin M, Wainstein J, Matas Z, Laudon M, Zisapel N. Efficacy and safety of prolonged-release melatonin in insomnia patients with diabetes: a randomized, double-blind, crossover study. Diabetes, metabolic syndrome and obesity: targets and therapy. 2011;4:307-313.
  164. Gringras P, Nir T, Breddy J, Frydman-Marom A, Findling RL. Efficacy and Safety of Pediatric Prolonged-Release Melatonin for Insomnia in Children With Autism Spectrum Disorder. Journal of the American Academy of Child & Adolescent Psychiatry. 2017;56(11):948-957.e944.
  165. Rosenwasser AM, Turek FW. Neurobiology of Circadian Rhythm Regulation. Sleep medicine clinics. 2015;10(4):403-412.
  166. Toh KL. Basic science review on circadian rhythm biology and circadian sleep disorders. Ann Acad Med Singapore. 2008;37(8):662-668.
  167. Mohawk JA, Green CB, Takahashi JS. Central and peripheral circadian clocks in mammals. Annu Rev Neurosci. 2012;35:445-462.
  168. Huang H, Li L, Shi W, et al. The Multifunctional Effects of Nobiletin and Its Metabolites In Vivo and In Vitro. Evidence-based complementary and alternative medicine: eCAM. 2016;2016:2918796.
  169. He B, Nohara K, Park N, et al. The Small Molecule Nobiletin Targets the Molecular Oscillator to Enhance Circadian Rhythms and Protect against Metabolic Syndrome. Cell metabolism. 2016;23(4):610-621.
  170. Gile J, Scott B, Eckle T. The Period 2 Enhancer Nobiletin as Novel Therapy in Murine Models of Circadian Disruption Resembling Delirium. Critical care medicine. 2018;46(6):e600-e608.
  171. Shinozaki A, Misawa K, Ikeda Y, et al. Potent Effects of Flavonoid Nobiletin on Amplitude, Period, and Phase of the Circadian Clock Rhythm in PER2::LUCIFERASE Mouse Embryonic Fibroblasts. PLoS One. 2017;12(2):e0170904.
  172. Richard DM, Dawes MA, Mathias CW, Acheson A, Hill-Kapturczak N, Dougherty DM. L-Tryptophan: Basic Metabolic Functions, Behavioral Research and Therapeutic Indications. Int J Tryptophan Res. 2009;2:45-60.
  173. Peuhkuri K, Sihvola N, Korpela R. Diet promotes sleep duration and quality. Nutr Res. 2012;32(5):309-319.
  174. Paredes SD, Barriga C, Reiter RJ, Rodriguez AB. Assessment of the Potential Role of Tryptophan as the Precursor of Serotonin and Melatonin for the Aged Sleep-wake Cycle and Immune Function: Streptopelia Risoria as a Model. Int J Tryptophan Res. 2009;2:23-36.
  175. Hartmann E, Cravens J, List S. Hypnotic effects of L-tryptophan. Archives of general psychiatry. 1974;31(3):394-397.
  176. Paredes SD, Marchena AM, Bejarano I, et al. Melatonin and tryptophan affect the activity-rest rhythm, core and peripheral temperatures, and interleukin levels in the ringdove: changes with age. The journals of gerontology Series A, Biological sciences and medical sciences. 2009;64(3):340-350.
  177. Hajak G, Huether G, Blanke J, et al. The influence of intravenous L-tryptophan on plasma melatonin and sleep in men. Pharmacopsychiatry. 1991;24(1):17-20.
  178. Silber BY, Schmitt JA. Effects of tryptophan loading on human cognition, mood, and sleep. Neuroscience and biobehavioral reviews. 2010;34(3):387-407.
  179. Lieberman HR, Agarwal S, Fulgoni VL, III. Tryptophan Intake in the US Adult Population Is Not Related to Liver or Kidney Function but Is Associated with Depression and Sleep Outcomes. The Journal of Nutrition. 2016;146(12):2609S-2615S.
  180. Bravo R, Matito S, Cubero J, et al. Tryptophan-enriched cereal intake improves nocturnal sleep, melatonin, serotonin, and total antioxidant capacity levels and mood in elderly humans. Age (Dordr). 2013;35(4):1277-1285.
  181. Fukushige H, Fukuda Y, Tanaka M, et al. Effects of tryptophan-rich breakfast and light exposure during the daytime on melatonin secretion at night. Journal of physiological anthropology. 2014;33:33.
  182. Razak MA, Begum PS, Viswanath B, Rajagopal S. Multifarious Beneficial Effect of Nonessential Amino Acid, Glycine: A Review. Oxidative medicine and cellular longevity. 2017;2017:1716701-1716701.
  183. Yamadera W, Inagawa K, Chiba S, Bannai M, Takahashi M, Nakayama K. Glycine ingestion improves subjective sleep quality in human volunteers, correlating with polysomnographic changes. Sleep and Biological Rhythms. 2007;5(2):126-131.
  184. Inagawa K, Hiraoka T, Kohda T, Yamadera W, Takahashi M. Subjective effects of glycine ingestion before bedtime on sleep quality. Sleep and Biological Rhythms. 2006;4(1):75-77.
  185. Bannai M, Kawai N, Ono K, Nakahara K, Murakami N. The effects of glycine on subjective daytime performance in partially sleep-restricted healthy volunteers. Frontiers in neurology. 2012;3:61-61.
  186. Kawai N, Sakai N, Okuro M, et al. The sleep-promoting and hypothermic effects of glycine are mediated by NMDA receptors in the suprachiasmatic nucleus. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology. 2015;40(6):1405-1416.
  187. Durlach J, Pages N, Bac P, Bara M, Guiet-Bara A. Biorhythms and possible central regulation of magnesium status, phototherapy, darkness therapy and chronopathological forms of magnesium depletion. Magnesium research: official organ of the International Society for the Development of Research on Magnesium. 2002;15(1-2):49-66.
  188. Supplements NIoHOoD. Magnesium. 2018.
  189. Frank S, Gonzalez K, Lee-Ang L, Young MC, Tamez M, Mattei J. Diet and Sleep Physiology: Public Health and Clinical Implications. Frontiers in neurology. 2017;8(393).
  190. Grandner MA, Jackson N, Gerstner JR, Knutson KL. Dietary nutrients associated with short and long sleep duration. Data from a nationally representative sample. Appetite. 2013;64:71-80.
  191. Nielsen FH. Chapter 31 - Relation between Magnesium Deficiency and Sleep Disorders and Associated Pathological Changes. In: Watson RR, ed. Modulation of Sleep by Obesity, Diabetes, Age, and Diet. San Diego: Academic Press; 2015:291-296.
  192. Omiya K, Akashi YJ, Yoneyama K, Osada N, Tanabe K, Miyake F. Heart-rate response to sympathetic nervous stimulation, exercise, and magnesium concentration in various sleep conditions. International journal of sport nutrition and exercise metabolism. 2009;19(2):127-135.
  193. Rondanelli M, Opizzi A, Monteferrario F, Antoniello N, Manni R, Klersy C. The effect of melatonin, magnesium, and zinc on primary insomnia in long-term care facility residents in Italy: a double-blind, placebo-controlled clinical trial. J Am Geriatr Soc. 2011;59(1):82-90.
  194. Hornyak M, Voderholzer U, Hohagen F, Berger M, Riemann D. Magnesium therapy for periodic leg movements-related insomnia and restless legs syndrome: an open pilot study. Sleep. 1998;21(5):501-505.
  195. Abumaria N, Yin B, Zhang L, et al. Effects of elevation of brain magnesium on fear conditioning, fear extinction, and synaptic plasticity in the infralimbic prefrontal cortex and lateral amygdala. J Neurosci. 2011;31(42):14871-14881.
  196. Slutsky I, Abumaria N, Wu LJ, et al. Enhancement of learning and memory by elevating brain magnesium. Neuron. 2010;65(2):165-177.
  197. Prasad AS. Zinc is an Antioxidant and Anti-Inflammatory Agent: Its Role in Human Health. Frontiers in nutrition. 2014;1:14-14.
  198. Cherasse Y, Urade Y. Dietary Zinc Acts as a Sleep Modulator. International journal of molecular sciences. 2017;18(11):2334.
  199. Ji X, Liu J. Associations between Blood Zinc Concentrations and Sleep Quality in Childhood: A Cohort Study. Nutrients. 2015;7(7):5684-5696.
  200. Cherasse Y, Saito H, Nagata N, Aritake K, Lazarus M, Urade Y. Zinc-containing yeast extract promotes nonrapid eye movement sleep in mice. Mol Nutr Food Res. 2015;59(10):2087-2093.
  201. Song CH, Kim YH, Jung KI. Associations of zinc and copper levels in serum and hair with sleep duration in adult women. Biol Trace Elem Res. 2012;149(1):16-21.
  202. Center UoRM. Valerian. 2019.
  203. Supplements NIoHOoD. Valerian. 2013.
  204. Shi Y, Dong J-W, Zhao J-H, Tang L-N, Zhang J-J. Herbal Insomnia Medications that Target GABAergic Systems: A Review of the Psychopharmacological Evidence. Current neuropharmacology. 2014;12(3):289-302.
  205. Kakehashi A, Kato A, Ishii N, et al. Valerian Inhibits Rat Hepatocarcinogenesis by Activating GABA(A) Receptor-Mediated Signaling. PLOS ONE. 2014;9(11):e113610.
  206. Taavoni S, Ekbatani N, Kashaniyan M, Haghani H. Effect of valerian on sleep quality in postmenopausal women: a randomized placebo-controlled clinical trial. Menopause (New York, NY). 2011;18(9):951-955.
  207. Choi H-S, Ko BS, Kim HD, Hong K-B, Suh HJ. Effect of Valerian/Hop Mixture on Sleep-Related Behaviors in <i>Drosophila melanogaster</i>. Biological and Pharmaceutical Bulletin. 2017;40(7):1101-1110.
  208. Ziegler G, Ploch M, Miettinen-Baumann A, Collet W. Efficacy and tolerability of valerian extract LI 156 compared with oxazepam in the treatment of non-organic insomnia--a randomized, double-blind, comparative clinical study. European journal of medical research. 2002;7(11):480-486.
  209. Kelber O, Nieber K, Kraft K. Valerian: No Evidence for Clinically Relevant Interactions. Evidence-Based Complementary and Alternative Medicine. 2014;2014:8.
  210. Fernandez-San-Martin MI, Masa-Font R, Palacios-Soler L, Sancho-Gomez P, Calbo-Caldentey C, Flores-Mateo G. Effectiveness of Valerian on insomnia: a meta-analysis of randomized placebo-controlled trials. Sleep Med. 2010;11(6):505-511.
  211. Anderson GD, Elmer GW, Taibi DM, et al. Pharmacokinetics of valerenic acid after single and multiple doses of valerian in older women. Phytother Res. 2010;24(10):1442-1446.
  212. Chen J-H, Chao Y-H, Lu S-F, Shiung T-F, Chao Y-F. The effectiveness of valerian acupressure on the sleep of ICU patients: A randomized clinical trial. International journal of nursing studies. 2012;49(8):913-920.
  213. Sanchez-Ortuno MM, Belanger L, Ivers H, LeBlanc M, Morin CM. The use of natural products for sleep: A common practice? Sleep Med. 2009;10(9):982-987.
  214. Zick SM, Wright BD, Sen A, Arnedt JT. Preliminary examination of the efficacy and safety of a standardized chamomile extract for chronic primary insomnia: A randomized placebo-controlled pilot study. BMC Complementary and Alternative Medicine. 2011;11(1):78.
  215. Srivastava JK, Shankar E, Gupta S. Chamomile: A herbal medicine of the past with bright future. Molecular medicine reports. 2010;3(6):895-901.
  216. Amsterdam JD, Shults J, Soeller I, Mao JJ, Rockwell K, Newberg AB. Chamomile (Matricaria recutita) may provide antidepressant activity in anxious, depressed humans: an exploratory study. Alternative therapies in health and medicine. 2012;18(5):44-49.
  217. Chang S-M, Chen C-H. Effects of an intervention with drinking chamomile tea on sleep quality and depression in sleep disturbed postnatal women: a randomized controlled trial. Journal of Advanced Nursing. 2016;72(2):306-315.
  218. Adib-Hajbaghery M, Mousavi SN. The effects of chamomile extract on sleep quality among elderly people: A clinical trial. Complementary therapies in medicine. 2017;35:109-114.
  219. Abdullahzadeh M, Naji SA. Effect of Chamomile Extract on Sleep Quality of the Elderly. Evidence Based Care. 2014;4(3):47-56.
  220. Miroddi M, Calapai G, Navarra M, Minciullo PL, Gangemi S. Passiflora incarnata L.: Ethnopharmacology, clinical application, safety and evaluation of clinical trials. Journal of ethnopharmacology. 2013;150(3):791-804.
  221. Nassiri-Asl M, Shariati-Rad S, Zamansoltani F. Anticonvulsant effects of aerial parts of Passiflora incarnata extract in mice: involvement of benzodiazepine and opioid receptors. BMC Complement Altern Med. 2007;7:26.
  222. Dhawan K, Kumar S, Sharma A. Comparative anxiolytic activity profile of various preparations of Passiflora incarnata linneaus: a comment on medicinal plants' standardization. Journal of alternative and complementary medicine (New York, NY). 2002;8(3):283-291.
  223. Appel K, Rose T, Fiebich B, Kammler T, Hoffmann C, Weiss G. Modulation of the gamma-aminobutyric acid (GABA) system by Passiflora incarnata L. Phytother Res. 2011;25(6):838-843.
  224. Maroo N, Hazra A, Das T. Efficacy and safety of a polyherbal sedative-hypnotic formulation NSF-3 in primary insomnia in comparison to zolpidem: a randomized controlled trial. Indian journal of pharmacology. 2013;45(1):34-39.
  225. Fahami F, Asali Z, Aslani A, Fathizadeh N. A comparative study on the effects of Hypericum Perforatum and passion flower on the menopausal symptoms of women referring to Isfahan city health care centers. Vol 152010.
  226. Dhawan K, Dhawan S, Chhabra S. Attenuation of benzodiazepine dependence in mice by a tri-substituted benzoflavone moiety of Passiflora incarnata Linneaus: a non-habit forming anxiolytic. Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques. 2003;6(2):215-222.
  227. Chandrasekhar K KJ, Anishetty S. . A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of Ashwagandha root in reducing stress and anxiety in adults. Indian journal of psychological medicine. 2012;34:255-262.
  228. Pratte MA, Nanavati KB, Young V, Morley CP. An alternative treatment for anxiety: a systematic review of human trial results reported for the Ayurvedic herb ashwagandha (Withania somnifera). Journal of alternative and complementary medicine (New York, NY). 2014;20(12):901-908.
  229. Archana R, Namasivayam A. Antistressor effect of Withania somnifera. Journal of ethnopharmacology. 1999;64(1):91-93.
  230. Bhattacharya SK, Bhattacharya A, Sairam K, Ghosal S. Anxiolytic-antidepressant activity of Withania somnifera glycowithanolides: an experimental study. Phytomedicine. 2000;7(6):463-469.
  231. Kumar A, Kalonia H. Protective effect of Withania somnifera Dunal on the behavioral and biochemical alterations in sleep-disturbed mice (Grid over water suspended method). Indian journal of experimental biology. 2007;45(6):524-528.
  232. Shah N, Singh R, Sarangi U, et al. Combinations of Ashwagandha Leaf Extracts Protect Brain-Derived Cells against Oxidative Stress and Induce Differentiation. PLOS ONE. 2015;10(3):e0120554.
  233. Ghosh T, Suke S, Yadav C, Ahmed R, Banerjee B. Ashwagandha reverses the dieldrin-induced cognitive impairment by modulation of oxidative stress in rat brain. Pharmacognosy Research. 2019;11(1):92-97.
  234. Kumar A, Kalonia H. Effect of Withania somnifera on Sleep-Wake Cycle in Sleep-Disturbed Rats: Possible GABAergic Mechanism. Indian J Pharm Sci. 2008;70(6):806-810.
  235. Manchanda S, Mishra R, Singh R, Kaur T, Kaur G. Aqueous Leaf Extract of Withania somnifera as a Potential Neuroprotective Agent in Sleep-deprived Rats: a Mechanistic Study. Molecular neurobiology. 2017;54(4):3050-3061.
  236. Kaushik MK, Kaul SC, Wadhwa R, Yanagisawa M, Urade Y. Triethylene glycol, an active component of Ashwagandha (Withania somnifera) leaves, is responsible for sleep induction. PLOS ONE. 2017;12(2):e0172508.
  237. Raines T, Jones P, Moe N, Duncan R, McCall S, Ceremuga TE. Investigation of the anxiolytic effects of luteolin, a lemon balm flavonoid in the male Sprague-Dawley rat. AANA journal. 2009;77(1):33-36.
  238. Weeks BS. Formulations of dietary supplements and herbal extracts for relaxation and anxiolytic action: Relarian. Med Sci Monit. 2009;15(11):Ra256-262.
  239. Kennedy DO, Little W, Scholey AB. Attenuation of laboratory-induced stress in humans after acute administration of Melissa officinalis (Lemon Balm). Psychosomatic medicine. 2004;66(4):607-613.
  240. Awad R, Muhammad A, Durst T, Trudeau VL, Arnason JT. Bioassay-guided fractionation of lemon balm (Melissa officinalis L.) using an in vitro measure of GABA transaminase activity. Phytother Res. 2009;23(8):1075-1081.
  241. Noguchi-Shinohara M, Ono K, Hamaguchi T, et al. Pharmacokinetics, Safety and Tolerability of Melissa officinalis Extract which Contained Rosmarinic Acid in Healthy Individuals: A Randomized Controlled Trial. PLoS One. 2015;10(5):e0126422.
  242. Cases J, Ibarra A, Feuillere N, Roller M, Sukkar SG. Pilot trial of Melissa officinalis L. leaf extract in the treatment of volunteers suffering from mild-to-moderate anxiety disorders and sleep disturbances. Mediterranean journal of nutrition and metabolism. 2011;4(3):211-218.
  243. Taavoni S, Nazem ekbatani N, Haghani H. Valerian/lemon balm use for sleep disorders during menopause. Complementary therapies in clinical practice. 2013;19(4):193-196.
  244. Muller SF, Klement S. A combination of valerian and lemon balm is effective in the treatment of restlessness and dyssomnia in children. Phytomedicine. 2006;13(6):383-387.
  245. Smith LA, L. HL, Kay S, Reilly R. Effect of Inhaled Lavender and Sleep Hygiene on Self-Reported Sleep Issues: A Randomized Controlled Trial. 2015;21(7):430-438.
  246. Chien LW, Cheng SL, Liu CF. The effect of lavender aromatherapy on autonomic nervous system in midlife women with insomnia. Evidence-based complementary and alternative medicine : eCAM. 2012;2012:740813.
  247. Conrad P, Adams C. The effects of clinical aromatherapy for anxiety and depression in the high risk postpartum woman - a pilot study. Complementary therapies in clinical practice. 2012;18(3):164-168.
  248. Hirokawa K, Nishimoto T, Taniguchi T. Effects of lavender aroma on sleep quality in healthy Japanese students. Perceptual and motor skills. 2012;114(1):111-122.
  249. Koulivand PH, Khaleghi Ghadiri M, Gorji A. Lavender and the nervous system. Evidence-based complementary and alternative medicine : eCAM. 2013;2013:681304-681304.
  250. Woelk H, Schlafke S. A multi-center, double-blind, randomised study of the Lavender oil preparation Silexan in comparison to Lorazepam for generalized anxiety disorder. Phytomedicine. 2010;17(2):94-99.
  251. Christodoulou E, Kadoglou NP, Kostomitsopoulos N, Valsami G. Saffron: a natural product with potential pharmaceutical applications. Journal of Pharmacy and Pharmacology. 2015;67(12):1634-1649.
  252. Broadhead GK, Chang A, Grigg J, McCluskey P. Efficacy and Safety of Saffron Supplementation: Current Clinical Findings. Critical Reviews in Food Science and Nutrition. 2016;56(16):2767-2776.
  253. Soeda S. AK, Urade Y., Sato H., Shoyama Y. . Neuroprotective Activities of Saffron and Crocin. In: Essa M, Akbar M, Guillemin G (eds) The Benefits of Natural Products for Neurodegenerative Diseases Advances in Neurobiology, . 2016 12.
  254. Liu Z, Xu X-H, Liu T-Y, et al. Safranal Enhances Non-Rapid Eye Movement Sleep in Pentobarbital-Treated Mice. CNS neuroscience & therapeutics. 2012;18(8):623-630.
  255. Shadadi H, Mansouri A, Azizollah A. Effect of oral saffron capsules on sleep quality in patients with diabetes at Zabol-Iran. Bali Medical Journal. 2017;6:595.
  256. Alexeev M, Grosenbaugh DK, Mott DD, Fisher JL. The natural products magnolol and honokiol are positive allosteric modulators of both synaptic and extra-synaptic GABA(A) receptors. Neuropharmacology. 2012;62(8):2507-2514.
  257. Arora S, Singh S, Piazza GA, Contreras CM, Panyam J, Singh AP. Honokiol: a novel natural agent for cancer prevention and therapy. Current molecular medicine. 2012;12(10):1244-1252.
  258. Talarek S, Listos J, Barreca D, et al. Neuroprotective effects of honokiol: from chemistry to medicine. BioFactors (Oxford, England). 2017;43(6):760-769.
  259. Qu WM, Yue XF, Sun Y, et al. Honokiol promotes non-rapid eye movement sleep via the benzodiazepine site of the GABA(A) receptor in mice. Br J Pharmacol. 2012;167(3):587-598.
  260. Kuribara H, Kishi E, Hattori N, Okada M, Maruyama Y. The anxiolytic effect of two oriental herbal drugs in Japan attributed to honokiol from magnolia bark. The Journal of pharmacy and pharmacology. 2000;52(11):1425-1429.
  261. Kuribara H, Stavinoha WB, Maruyama Y. Behavioural pharmacological characteristics of honokiol, an anxiolytic agent present in extracts of Magnolia bark, evaluated by an elevated plus-maze test in mice. The Journal of pharmacy and pharmacology. 1998;50(7):819-826.
  262. Kuribara H, Stavinoha WB, Maruyama Y. Honokiol, a putative anxiolytic agent extracted from magnolia bark, has no diazepam-like side-effects in mice. The Journal of pharmacy and pharmacology. 1999;51(1):97-103.
  263. Wang L, Ma R, Liu C, et al. Salvia miltiorrhiza: A Potential Red Light to the Development of Cardiovascular Diseases. Current pharmaceutical design. 2017;23(7):1077-1097.
  264. Lai X-J, Zhang L, Li J-S, et al. Comparative pharmacokinetic and bioavailability studies of three salvianolic acids after the administration of Salviae miltiorrhizae alone or with synthetical borneol in rats. Fitoterapia. 2011;82(6):883-888.
  265. Huiyun Z, Rong O. THE INHIBITORY EFFECT OF SALVIA MILTRIORRHIZA BGE ON THE CENTRAL NERVOUS SYSTEM [J]. Acta Pharmaceutica Sinica. 1979;5.
  266. Kim JH, Desor D, Kim YT, et al. Efficacy of alphas1-casein hydrolysate on stress-related symptoms in women. European journal of clinical nutrition. 2007;61(4):536-541.
  267. Saint-Hilaire Zd, Messaoudi M, Desor D, Kobayashi T. Effects of a bovine alpha S1-Casein tryptic hydrolysate (CTH) on sleep disorder in Japanese general population. The Open Sleep Journal. 2009;2(1).
;